Here We Go Again: Omicron Forces FDA To Pause ‘Certain Inspectional Activities’

The COVID-19 pandemic’s latest variant has pushed the US FDA to pump the brake once again on performing on-site surveillance inspections through at least 19 January. Meanwhile, an agency official says Remote Regulatory Assessments “are here to stay.”